X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with FDC LTD. - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs FDC LTD. - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA FDC LTD. AJANTA PHARMA/
FDC LTD.
 
P/E (TTM) x 24.2 28.9 83.8% View Chart
P/BV x 10.0 6.0 165.7% View Chart
Dividend Yield % 0.6 0.8 76.5%  

Financials

 AJANTA PHARMA   FDC LTD.
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-16
FDC LTD.
Mar-14
AJANTA PHARMA/
FDC LTD.
5-Yr Chart
Click to enlarge
High Rs1,720144 1,198.6%   
Low Rs1,10379 1,396.2%   
Sales per share (Unadj.) Rs194.647.6 409.1%  
Earnings per share (Unadj.) Rs45.27.6 594.3%  
Cash flow per share (Unadj.) Rs50.39.0 558.2%  
Dividends per share (Unadj.) Rs8.002.25 355.6%  
Dividend yield (eoy) %0.62.0 28.0%  
Book value per share (Unadj.) Rs132.047.5 277.8%  
Shares outstanding (eoy) m88.77177.83 49.9%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x7.32.3 310.1%   
Avg P/E ratio x31.214.6 213.5%  
P/CF ratio (eoy) x28.112.3 227.3%  
Price / Book Value ratio x10.72.3 456.8%  
Dividend payout %17.729.6 59.8%   
Avg Mkt Cap Rs m125,29919,784 633.3%   
No. of employees `000NANA-   
Total wages/salary Rs m2,5701,221 210.6%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m17,2758,459 204.2%  
Other income Rs m166394 42.3%   
Total revenues Rs m17,4428,852 197.0%   
Gross profit Rs m5,8072,070 280.5%  
Depreciation Rs m451249 180.9%   
Interest Rs m4931 157.7%   
Profit before tax Rs m5,4742,184 250.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-225 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,460606 241.1%   
Profit after tax Rs m4,0141,353 296.6%  
Gross profit margin %33.624.5 137.4%  
Effective tax rate %26.727.7 96.2%   
Net profit margin %23.216.0 145.2%  
BALANCE SHEET DATA
Current assets Rs m7,6394,355 175.4%   
Current liabilities Rs m2,7151,792 151.5%   
Net working cap to sales %28.530.3 94.1%  
Current ratio x2.82.4 115.8%  
Inventory Days Days4344 97.3%  
Debtors Days Days7925 319.0%  
Net fixed assets Rs m6,9143,025 228.6%   
Share capital Rs m177179 99.0%   
"Free" reserves Rs m11,4428,243 138.8%   
Net worth Rs m11,7218,453 138.7%   
Long term debt Rs m14911 1,389.7%   
Total assets Rs m14,81410,557 140.3%  
Interest coverage x112.971.4 158.1%   
Debt to equity ratio x00 1,002.3%  
Sales to assets ratio x1.20.8 145.5%   
Return on assets %27.413.1 209.2%  
Return on equity %34.216.0 213.9%  
Return on capital %46.523.5 197.9%  
Exports to sales %55.113.3 414.4%   
Imports to sales %6.03.3 179.6%   
Exports (fob) Rs m9,5271,126 846.3%   
Imports (cif) Rs m1,038283 366.9%   
Fx inflow Rs m10,4221,146 909.3%   
Fx outflow Rs m1,678355 472.3%   
Net fx Rs m8,744791 1,105.7%   
CASH FLOW
From Operations Rs m3,2641,485 219.8%  
From Investments Rs m-2,093-620 337.8%  
From Financial Activity Rs m-1,186-753 157.6%  
Net Cashflow Rs m-15113 -13.1%  

Share Holding

Indian Promoters % 73.8 68.9 107.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 4.7 33.0%  
FIIs % 7.6 7.5 101.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 19.0 89.5%  
Shareholders   20,968 23,730 88.4%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   TORRENT PHARMA  NATCO PHARMA  BIOCON LTD  PFIZER  ALKEM LABORATORIES  

Compare AJANTA PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes Marginally Lower; Capital Goods & Realty Stocks Fall(Closing)

Indian share markets witnessed selling pressure in the final hour of trade to finish just below the dotted line. At the closing bell, the BSE Sensex closed lower by 71 points.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Feb 20, 2018 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 5-YR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS